Investigating the role of a key enzyme in leukemia development
The Role of DLST in Leukemogenesis
['FUNDING_R01'] · BOSTON UNIVERSITY MEDICAL CAMPUS · NIH-10472483
This study is looking at how a certain enzyme might play a role in tough-to-treat leukemia, with the hope of finding new ways to help patients by understanding the changes in leukemia cells.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | BOSTON UNIVERSITY MEDICAL CAMPUS (nih funded) |
| Locations | 1 site (BOSTON, UNITED STATES) |
| Trial ID | NIH-10472483 on ClinicalTrials.gov |
What this research studies
This research focuses on understanding how a specific enzyme, dihydrolipoamide S-succinyltransferase (DLST), contributes to the development of leukemia, particularly in treatment-resistant cases. By studying the metabolic changes in leukemic cells, the researchers aim to uncover new therapeutic strategies that target these unique metabolic pathways. The approach involves examining the enzyme's role in the tricarboxylic acid (TCA) cycle and its impact on cell survival and proliferation in leukemia. Patients may benefit from insights that could lead to more effective treatments for leukemia.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with leukemia, particularly those who have experienced treatment resistance.
Not a fit: Patients with non-malignant conditions or those without a diagnosis of leukemia may not receive any benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to novel therapies that improve survival rates for leukemia patients facing drug resistance.
How similar studies have performed: Other research has shown promise in targeting metabolic pathways in cancer treatment, suggesting that this approach could be effective.
Where this research is happening
BOSTON, UNITED STATES
- BOSTON UNIVERSITY MEDICAL CAMPUS — BOSTON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: FENG, HUI — BOSTON UNIVERSITY MEDICAL CAMPUS
- Study coordinator: FENG, HUI
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Cancers, neoplasm/cancer